TheOctopus
Banned
- Joined
- Apr 4, 2013
- Messages
- 1,622
- Thread Author
- #1
In what has become an all too familiar—and depressing—outcome in the decades long search for an effective AIDS vaccine, yet another candidate has failed in a large-scale study.
A vaccine made by Johnson & Johnson (J&J) offered no convincing protection against HIV infection in the trial, dubbed Imbokodo, which began in 2017 and involved 2600 women in South Africa and four neighboring countries. “We have to fundamentally relook at what we’re doing,” says Glenda Gray, who heads the South African Medical Research Council and oversaw the protocol for the trial, which compared the efficacy of the vaccine to a placebo.
Link to article-- AAAS
A vaccine made by Johnson & Johnson (J&J) offered no convincing protection against HIV infection in the trial, dubbed Imbokodo, which began in 2017 and involved 2600 women in South Africa and four neighboring countries. “We have to fundamentally relook at what we’re doing,” says Glenda Gray, who heads the South African Medical Research Council and oversaw the protocol for the trial, which compared the efficacy of the vaccine to a placebo.
Link to article-- AAAS